40 results about "Atrophic spinal cord" patented technology

Disclosed is the family of genes responsible for the neurodegenerative diseases, particularly Amyotrophic Lateral Sclerosis. Methods and compounds for the diagnosis, prevention, and therapy of the disease are also disclosed.

The present invention relates to compositions and methods for the treatment of neurological disorders related to glutamate excitotoxicity and Amyloid β toxicity. More specifically, the present invention relates to novel combinatorial therapies of Multiple Sclerosis, Alzheimer's disease, Alzheimer's disease related disorders, Amyotrophic Lateral Sclerosis, Parkinson's disease, Huntington's disease, neuropathic pain, alcoholic neuropathy, alcoholism or alcohol withdrawal, or spinal cord injury.

Disclosed are methods for generating a neuron expressing Hoxc8 transcription factor or a caudal motor neuron comprising culturing an embryonic stem cell in a composition which is essentially free of retinoids and comprises an isotonic salt solution, so as to generate the neuron which expresses Hoxc8 transcription factor or the caudal motor neuron. Disclosed are also methods for generating a caudal brachial motor neuron, a thoracic motor neuron, or a lumbar motor neuron from an embryonic stem cell in a composition essentially free of retinoids and comprising ADFNK medium, an amount of FGF-2, or Gdf11 respectively. Disclosed are also methods of transplanting a motor neuron into a subject comprising generating the motor neuron and transplanting the motor neuron into the subject. Disclosed is also a population of motor neuron cells enriched for motor neuron cells expressing Foxp1 and expressing a gene associated with Spinal Muscular Atrophy (SMA) or Amyotrophic Lateral Sclerosis (ALS).

The present invention relates to combinations and methods for the treatment of neurological disorders related to glutamate excitotoxicity and Amyloid β toxicity. More specifically, the present invention relates to novel combinatorial therapies of Multiple Sclerosis, Alzheimer's disease, Alzheimer's disease related disorder, Amyotrophic Lateral Sclerosis, Parkinson's disease, Huntington's disease, neuropathic pain, alcoholic neuropathy, alcoholism or alcohol withdrawal, or spinal cord injury, based on Baclofen and Acamprosate combination.

A method for treating patients with Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease. In accordance with the method of treatment, transcranial AC pulsed electromagnetic fields (EMFs) in substantially square waveforms in particular frequency and amplitude ranges and picotesla quantities are applied to the patient's brain. EMFs are applied via a transducer array containing a plurality of flexible circular coils in an arrangement placed over the scalp of an ALS patient. The treatment method ameliorates symptoms associated with the disease state and slows the progression of the disease.

Provided herein are methods of treatment of Amyotrophic Lateral Sclerosis comprising administration of adrenocorticotropic hormone (ACTH), or fragment, analog, complex or aggregate thereof, or any combination thereof, to an individual in need thereof.

Disclosed are methods for treating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis, Alzheimer's Disease, Parkinson's Disease, Myasthenia Gravis, Multifocal Motor Neuropathy, Primary Lateral Sclerosis, Spinal Muscular Atrophy, Kennedy's Disease, and Spinocerebellar Ataxia, by administration of a compound that blocks the interaction of CD40 and CD40L.

Peptides derived from anti-inflammatory cytokines, such as IL-10, are disclosed for use in treatment of neurodegenerative diseases and neuropathic pain indications, including Alzheimer's disease, Amyotrophic Lateral Sclerosis, Multiple Sclerosis, Parkinson's disease and trigeminal neuralgia.

A method of diagnosing Amyotrophic Lateral Sclerosis (ALS) is disclosed. The method comprising determining a level of miR-218 in a biological sample of a subject, wherein a down-regulation in the miR-218 is indicative of ALS in the subject.

The invention discloses application of carboxyl aminotriazole or pharmaceutically acceptable salts of the carboxyl aminotriazole in the preparation of medicaments for preventing and / or treating neurodegenerative diseases, amyotrophic lateral sclerosis and inflammatory bowel diseases and also relates to the medicament packages or kits comprising the medicaments.

The present invention generally relates to methods of detecting and profiling progression of the risk of neurodegenerative diseases in a subject. In one embodiment, the method includes isolating a stem cell from cerebrospinal fluid of the subject and determining the level of H3K27 methylation within the stem cell. The subject is determined to have an increased risk of developing the neurodegenerative disease if the level of H3K27 methylation is elevated. In various embodiments, the neurodegenerative disease is Alzheimer's Disease, Parkinson's Disease or Amyotrophic Lateral Sclerosis.

L-serine, L-serine precursors, L-serine derivatives and L-serine conjugates for treatment, amelioration and / or prevention of protein aggregation / tangles / plaques and diseases associated with protein aggregation / tangles / plaques. In particular, treatments and uses for L-serine, L-serine precursors, L-serine derivatives and L-serine conjugates include Alzheimer's disease (AD), Parkinson's disease, Amyotrophic Lateral Sclerosis (ALS), and Huntington disease (HD).

Disclosed are methods for treating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis, Alzheimer's Disease Parkinson's Disease, Myasthenia Gravis, Multifocal Motor Neuropathy, Primary Lateral Sclerosis, Spinal Muscular Atrophy, Kennedy's Disease, and Spinocerebellar Ataxia.

The described invention relates to the use of the TAT-BH4 peptide for treating or preventing the progression of ALS. The methods include, postponing the appearance of symptoms and improving motor performance and survival in ALS. Methods are also provided, wherein the TAT-BH4 peptide is in a composition further comprising a pharmaceutically acceptable excipient.

The invention relates to a combination drug therapy composition used for treating amyotrophic lateral sclerosis and a preparation method and use thereof. The composition includes chlorogenic acid, vitamin E, vitamin C, coenzyme Q10, creatine phosphate sodium and a pharmaceutically acceptable carrier, wherein the chlorogenic acid, the vitamin E, the vitamin C, the coenzyme Q10, and the creatine phosphate sodium are unit preparations having same or different specifications and are administrated separately or together. After combination of the chlorogenic acid, the vitamin E, the vitamin C, the coenzyme Q10, and the creatine phosphate sodium, unexpected synergistic treatment effect on the amyotrophic lateral sclerosis is achieved, and therefore, the composition used for treating the amyotrophic lateral sclerosis and having excellent treatment effect is provided, and the composition can obviously delay disease progression of the amyotrophic lateral sclerosis.

The present invention relates to biomarkers, to their use and to a method for diagnosing in vitro or detecting the progression of a neurodegenerative disease in an individual, in particular for Amyotrophic Lateral Sclerosis (ALS). The method comprises the steps of isolating a biological sample from the individual; quantifying the level of one or more polypeptides in the biological sample according to the invention; comparing the obtained level with a reference level.

The invention discloses the application of gastrodine to the preparation of caspase-3 active inhibitor and belongs to the field of pharmacy. The gastrodine is applied to the preparation of caspase-3 active inhibitor, the caspase-3 active inhibitor can be used for treating diseases including neurodegenerative diseases, cardiovascular and cerebrovascular diseases, osteoarthritis, rheumatoid arthritis, and the like, specifically such as Parkinson disease, Alzheimer disease, amyotrophic lateral sclerosis, Huntington disease, traumatic brain injury, spinal cord injury, severe hepatitis, liver dysfunction, osteoarthritis, rheumatoid arthritis, acquired immunodeficiency syndrome, myocardial infarction, cerebral ischemia and the like. The application of gastrodine has the advantage of blocking the specific protease needed by apoptosis without any adverse reaction which is caused by the application of the majority of broad spectrum drugs.

Provided is a cell therapeutic agent for treatment of neurological disorders, comprising skin-derived progenitor cells (SPCs). More specifically, the present invention provides a cell therapeutic agent for treatment of neurological disorders, comprising skin-derived progenitor cells (SPCs) isolated from skin tissues and a method for differentiation of the skin-derived progenitor cells (SPCs) into neural cell lineages. The cell therapeutic agent in accordance with the present invention is therapeutically effective for the treatment of the neurological disorders and diseases such as Parkinson's disease, Alzheimer's disease, Huntington's disease and Amyotrophic Lateral Sclerosis (ALS) caused by neural injury, and neurological deficits due to cerebral apoplexy, ischemia and spinal cord injury. Further, the present invention enables transplantation of autologous cells to thereby minimize adverse side effects.

A gene therapy method, which is mediated with a gene vector (including, but not limited to 9 type adeno-associated viruses), directly edits a superoxide dismutase 1 (SOD1, for short) mutant gene based on a CRISPR / Cas9 gene editing system, and treats amyotrophic lateral sclerosis (ALS, for short) in vitro and in transgenic mice, is provided by the invention. A provided recombinant virus has bioactivity, and is hoped to be a candidate virus for ALS gene therapy.

The invention relates to a novel application of ginsenoside Rd in preparing a drug for treating microglial cell mediated diseases, and particularly relates to a novel application of ginsenoside Rd in preparing a drug for treating diseases such as disseminated sclerosis, amyotrophic lateral sclerosis, HIV-associated dementia, mad cow disease and the like.

The invention relates to the technical field of ultrasound combined microbubbles, in particular to medicine for treating amyotrophic lateral sclerosis by using an ultrasound combined microbubble technology and a method for enhancing a blood-brain barrier opening effect. Through the medicine and the method provided by the invention, the brain medicine / blood medicine proportion percentage of edaravone entering the brain can be increased. In mouse experiments, the medicine is combined with ultrasound for opening the blood-brain barrier of a mouse to deliver edaravone into the brain; after 4 weeksof treatment, the paw gripping force of the mouse in an ultrasound combined microbubble administration group is improved by 10.57 percent (p is smaller than 0.05) through being compared with that ofa model group; and the retention time on a rotating rod is prolonged by 79.8 percent (p is smaller than 0.01) through being compared with that of the mouse in the model group, and is prolonged by 57.3percent (p is smaller than 0.05) through being compared with that of an Eda group. The results show that compared with a conventional administration mode, the mode of delivering edaravone into the brain by ultrasound combined microbubbles has the advantages that the Brain bioavailability can be improved; and the disease progression of SOD1 mice is more effectively delayed.

The invention discloses application of ramulus et folium picrasmae extract to preparing medicines or healthcare products for preventing and treating neurodegenerative diseases. The ramulus et folium picrasmae extract comprises ramulus et folium picrasmae ethyl acetate extract and / or beta-carboline alkaloid separated from ramulus et folium picrasmae. The neurodegenerative diseases include Alzheimer's diseases, Parkinson's diseases, dementia with Lewy bodies, frontotemporal dementia, Huntington's diseases and amyotrophic lateral sclerosis. The application has the advantage that novel treatment pathways further can be provided to preventing and / or treating the neurodegenerative diseases.

The present invention relates to compositions and methods for the treatment of neurological disorders related to glutamate excitotoxicity and Amyloid β toxicity. More specifically, the present invention relates to novel combinatorial therapies of Multiple Sclerosis, Alzheimer's disease, Alzheimer's disease related disorders, Amyotrophic Lateral Sclerosis, Parkinson's disease, Huntington's disease, neuropathic pain, alcoholic neuropathy, alcoholism or alcohol withdrawal, or spinal cord injury.

The present discloses a method to treat stroke, spinal cord injury, Parkinson disease, multiple sclerosis (MS), Parkinson disease, Amyotrophic Lateral Sclerosis (ALS), and other neurological as well as diabetes with bone marrow transplantation. The said bone marrow is transplanted as a whole, and does not need any cell isolation and cell expansion.

The present invention provides a method for providing neuroprotection to the central or peripheral nervous system of a subject in need of such neuroprotection, which comprises periodically administering to the subject a certain amount of glatiramer acetate and a certain amount of 2-amino-6 - Trifluoromethoxybenzothiazole, wherein said amount is effective to provide neuroprotection to said subject's central or peripheral nervous system when taken together. The present invention also provides a package comprising glatiramer acetate, 2-amino-6-trifluoromethoxybenzothiazole, and a composition for use together to provide neuroprotection to the central or peripheral nervous system of a subject in need of such neuroprotection. Neuroprotective Instructions for Use. Furthermore, the present invention provides a pharmaceutical composition comprising an amount of glatiramer acetate and an amount of 2-amino-6-trifluoromethoxybenzothiazole, wherein said amounts are effective to provide for Neuroprotection of the subject's central or peripheral nervous system. The present invention also provides a pharmaceutical combination comprising a certain amount of glatiramer acetate and a certain amount of 2-amino-6-trifluoromethoxybenzothiazole in separate dosage forms, the combination is effective for providing Neuroprotection of the central or peripheral nervous system. Additionally, the combination therapy may be used to treat a subject afflicted with multiple sclerosis or a subject afflicted with amyotrophic lateral sclerosis.

Methods of selecting a subject for treatment of amyotrophic lateral sclerosis (ALS) and methods of treatment for subjects having ALS or at risk of developing ALS are provided. The method of selecting subjects for treatment includes obtaining a biological sample from the subject, where the sample is obtained from the subject's gastrointestinal tract or skeletal muscle. The method further includes measuring a biomarker in the subject's sample and selecting the subject for treatment of ALS when the biomarker measurement in the subject's sample is lower or higher relative to a control measurement.